Fallopian Tube Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 30 expanded access programs, clinical trials, and compassionate use pathways listed for Fallopian Tube Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with fallopian tube cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 13 programs are currently active or recruiting, with the remaining 17 in other lifecycle stages. Sponsors actively running programs in this area include AbbVie, Imunon, Alexander B Olawaiye, MD, Andrea Jewell, Artios Pharma Ltd, and others.
By recruiting status
Snapshot of where every Fallopian Tube Cancer program currently sits in its lifecycle.
- Active / Recruiting13
- Inactive17
Top sponsors
Organisations running the most Fallopian Tube Cancer programs in the directory.
- AbbVie4 programs
- Imunon3 programs
- Alexander B Olawaiye, MD1 program
- Andrea Jewell1 program
- Artios Pharma Ltd1 program
- Avenzo Therapeutics, Inc.1 program
- Beth Israel Deaconess Medical Center1 program
- Brown University1 program
- Corcept Therapeutics1 program
- Day One Biopharmaceuticals, Inc.1 program
Fallopian Tube Cancer programs (30)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Rucaparib and Nivolumab as Maintenance Treatment for Ovarian Cancer After Initial Chemotherapy — pharmaand GmbH
- Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on the Effectiveness of Carboplatin and Mirvetuximab Soravtansine for Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer — AbbVie
- Study on the Effects and Safety of IMGN151 for Gynecologic Cancers, Alone or with Other Treatments — AbbVie
- Study on Nivolumab with or without Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas — Brown University
- CATALINA-2: Study of TORL-1-23 for Treating Platinum-resistant Ovarian Cancer — TORL Biotherapeutics, LLC
- Study on HIPEC as Initial Treatment for Advanced Ovarian Cancer — Mercy Medical Center
- Study on Mirvetuximab Soravtansine with Carboplatin for Second-line Treatment of Folate Receptor Alpha Positive, Platinum-sensitive Ovarian Cancer — AbbVie
- Study on PARP Inhibitor and CTLA-4 Blocker for BRCA-Related Ovarian Cancer — New Mexico Cancer Research Alliance
- Phase 3 Study on the Safety and Effectiveness of IMNN-001 with Chemotherapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer — Imunon
- Study on Relacorilant with Nab-paclitaxel and Bevacizumab for Advanced Ovarian, Peritoneal, or Fallopian-Tube Cancer — Corcept Therapeutics
- Study of IMNN-001 with Chemotherapy for Treating Ovarian Cancer (OVATION 2) — Imunon
- Study of Senaparib and Temozolomide for Ovarian Cancer with ARID1A Mutation — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on ART0380 for Treating Advanced or Metastatic Solid Tumors — Artios Pharma Ltd
- Study on ZN-c3 and Niraparib for Patients with Platinum-Resistant Ovarian Cancer — K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or REGN4018 for Ovarian and Uterine Cancer — Regeneron Pharmaceuticals
- Study on Maintenance Therapy with Mirvetuximab Soravtansine and Olaparib for Ovarian Cancer — University of Colorado, Denver
- Study on Bevacizumab for Ovarian Cancer Found During Second-Look Surgery — M.D. Anderson Cancer Center
- Study on the Effectiveness and Safety of Olvi-Vec with Chemotherapy and Bevacizumab for Platinum-Resistant Ovarian Cancer — Genelux Corporation
- Study on Heated Chemotherapy for Primary Ovarian Cancer Patients — Andrea Jewell
- Study on Mirvetuximab Soravtansine with Bevacizumab vs. Bevacizumab for Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) — AbbVie
- Study on ONC-392 and Pembrolizumab for Treating Platinum-Resistant Ovarian Cancer — OncoC4, Inc.
- Phase II Study of IMNN-001 with Chemotherapy and BEV for Newly Diagnosed Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Imunon
- Study on Luveltamab Tazevibulin vs. Chemotherapy for Women with Ovarian Cancer Expressing FOLR1 — Sutro Biopharma, Inc.
- Study on PRO1184 for Advanced Solid Tumors — Genmab
- Study of AVZO-021 for Patients with Advanced Solid Tumors — Avenzo Therapeutics, Inc.
- Study on Chemotherapy with Pembrolizumab Followed by Maintenance with Olaparib for First-Line Treatment of Women with Advanced Ovarian Cancer Without BRCA Mutation — Merck Sharp & Dohme LLC
- Study on Vaccination for Ovarian Cancer Patients Using Dendritic Cell/Tumor Fusions with GM-CSF and Imiquimod — Beth Israel Deaconess Medical Center
- Study on ZEN003694 and Talazoparib for Patients with Recurrent Ovarian Cancer — Alexander B Olawaiye, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Fallopian Tube Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.